INTERVIEW: ImmunoGen prepares to capitalize on Kadcyla
This article was originally published in Scrip
ImmunoGen is preparing to capitalize on US FDA approval in February for Kadcyla (ado trastuzumab emtansine) - the first approved cancer therapy that incorporates the Waltham, Massachusetts-based company's antibody-drug conjugate (ADC) technology.
You may also be interested in...
The response rate, with five complete responses, exceeds known responses to standard-of-care chemotherapy in heavily pre-treated folate receptor alpha-high patients. A US FDA filing is on track for early 2022.
The company launched Amjevita on the same day it announced fourth quarter 2022 earnings and provided 2023 guidance, upping the high-profile nature of the first-to-market US Humira biosimilar.
Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.